Search in the Abstract Database

Search Abstracts 2013

* = Presenting author

P354. The bone mineral density in patients with inflammatory bowel disease (IBD), depending on clinical parameters of disease

E. Belousova1, A. Dreval1, M. Turbina1, 1Moscow Regional Research Clinical Institute, Moscow, Russian Federation

Background

Frequent decline of bone mineral density (BMD) including osteopenia and steoporosis in IBD patients usually considered to associate with corticosteroid treatment. We didn't find the data about severity of BMD in different course of IBD.

Purpose: To evaluate the degree of reduction of the bone mineral density (BMD) in IBD patients according to the severity and duration of disease.

Methods

79 IBD patients were examined: 21-CD, 58-UC. Mean age 28.6 years in the range 18–40 years, M: F = 2.2:1, an average disease duration 2.8 years (2 months-11 years). Inclusion criteria were: age 20–40 years, the absence of other causes that can help reduce the BMD (endocrine diseases, drugs, age). Clinical parameters of the disease were evaluated by rutine methods (endoscopy, clinical activity indexes), the BMD was measured by dual energy X-ray absorptiometry (DXA).

Results

According to duration of the disease patients were divided into 4 groups: I group – new cases of IBD, II – 1–3 years, III – 3–5 years, IV – more than 5 years. BMD decrease of varying severity was detected in 38% (n = 30) of patients. In I–IV patient groups the frequency of BMD reduction, including osteopenia and osteoporosis, was observed in 12.7%, 11.3%, 8.9% and 5.1% of cases respectively (p = 0.01 between groups I and IV). On the severity of disease patients were divided into 3 groups: mild, moderate, severe. There was a significant increase in frequency of BMD reduction according to severity of IBD: 1.3% in mild, 15.2% in moderate and 21.5% in severe IBD.

Conclusion

1) Decline of the frequency of BMD in IBD patients was significantly increased with increasing of disease severity. 2) Reduction in BMD was significantly more common in IBD patients with newly diagnosed disease and its incidence decreases as the duration of disease.